XML 68 R51.htm IDEA: XBRL DOCUMENT
v3.22.4

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Segment Reporting [Abstract] |
Schedule of Revenue from Segments to Consolidated | The following tables present our segment information (in thousands):
| Evolent Health Services |  | Clinical Solutions |  | Intersegment Eliminations |  | Subtotal |  | Corporate (1) |  | Consolidated Total
Revenue |  |  |  |  |  |  |  |  |  |  |
For the Year Ended December 31, 2022 |  |  |  |  |  |  |  |
Total revenue | $ | 408,371 |  |  | $ | 944,511 |  |  | $ | (869) |  |  | $ | 1,352,013 |  |  | $ | — |  |  | $ | 1,352,013 |
For the Year Ended December 31, 2021 |  |  |  |  |  |  |  |
Total revenue | $ | 311,627 |  |  | $ | 598,144 |  |  | $ | (1,814) |  |  | $ | 907,957 |  |  | $ | — |  |  | $ | 907,957 |
For the Year Ended December 31, 2020 |  |  |  |  |  |  |  |
Total revenue | $ | 385,134 |  |  | $ | 542,279 |  |  | $ | (2,774) |  |  | $ | 924,639 |  |  | $ | — |  |  | $ | 924,639 |
| Evolent Health Services |  | Clinical Solutions |  | Subtotal |  | Corporate (1) |  | Consolidated Total |  |
For the Year Ended December 31, 2022 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 57,936 |  |  | $ | 78,639 |  |  | $ | 136,575 |  |  | $ | (30,244) |  |  | $ | 106,331 |  |  |
For the Year Ended December 31, 2021 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 17,063 |  |  | $ | 82,920 |  |  | $ | 99,983 |  |  | $ | (33,666) |  |  | $ | 66,317 |  |  |
For the Year Ended December 31, 2020 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 57,731 |  |  | $ | 26,864 |  |  | $ | 84,595 |  |  | $ | (36,022) |  |  | $ | 48,573 |  |  |
———————— (1)Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.
Schedule of Reconciliation of Adjusted EBITDA to Net Loss | The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands):
|  |  | For the Year Ended December 31,
|  |  |  |  | 2022 |  | 2021 |  | 2020
Net loss attributable to common shareholders of Evolent Health, Inc. |  |  |  |  | $ | (19,164) |  |  | $ | (37,601) |  |  | $ | (334,246) |
Less: |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  | 1,369 |  |  | 407 |  |  | 2,633 |
Interest expense |  |  |  |  | (15,572) |  |  | (25,425) |  |  | (28,325) |
Benefit from (provision for) income taxes |  |  |  |  | 43,376 |  |  | (483) |  |  | 2,368 |
Depreciation and amortization expenses |  |  |  |  | (67,195) |  |  | (60,037) |  |  | (60,835) |
Equity method investment impairment |  |  |  |  | — |  |  | — |  |  | (47,133) |
Gain on transfer of membership |  |  |  |  | — |  |  | 45,938 |  |  | — |
Change in tax receivable agreement liability |  |  |  |  | (45,950) |  |  | — |  |  | — |
Loss on extinguishment/repayment of debt, net |  |  |  |  | (10,192) |  |  | (21,343) |  |  | (4,789) |
Goodwill impairment |  |  |  |  | — |  |  | — |  |  | (215,100) |
Gain from equity method investees |  |  |  |  | 4,569 |  |  | 13,179 |  |  | 10,039 |
Loss on disposal of assets |  |  |  |  | — |  |  | — |  |  | (698) |
Change in fair value of contingent consideration |  |  |  |  | 23,522 |  |  | (13,281) |  |  | (3,860) |
Other income (expense), net |  |  |  |  | 57 |  |  | (146) |  |  | (118) |
Repositioning costs |  |  |  |  | — |  |  | (7,318) |  |  | (1,275) |
Stock-based compensation expense |  |  |  |  | (33,981) |  |  | (16,711) |  |  | (14,606) |
Severance costs |  |  |  |  | (13,265) |  |  | (198) |  |  | (8,986) |
Amortization of contract cost assets |  |  |  |  | (99) |  |  | (476) |  |  | (3,944) |
Strategy and shareholder advisory expenses |  |  |  |  | — |  |  | (6,513) |  |  | — |
Acquisition costs |  |  |  |  | (11,671) |  |  | (4,194) |  |  | (2,116) |
Loss from discontinued operations (1) |  |  |  |  | (463) |  |  | (7,317) |  |  | (6,074) |
Adjusted EBITDA |  |  |  |  | $ | 106,331 |  |  | $ | 66,317 |  |  | $ | 48,573 |
———————— (1)Includes $0.5 million and $6.8 million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration